Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Operating Leases (2023 - 2025)

CG Oncology (CGON) has disclosed Operating Leases for 3 consecutive years, with $3.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Leases rose 5873.08% year-over-year to $3.1 million, compared with a TTM value of $3.1 million through Dec 2025, up 5873.08%, and an annual FY2025 reading of $3.1 million, up 5873.08% over the prior year.
  • Operating Leases was $3.1 million for Q4 2025 at CG Oncology, down from $3.3 million in the prior quarter.
  • Across five years, Operating Leases topped out at $3.3 million in Q3 2025 and bottomed at $52000.0 in Q4 2024.
  • Average Operating Leases over 3 years is $954555.6, with a median of $244000.0 recorded in 2023.
  • The sharpest move saw Operating Leases crashed 78.69% in 2024, then skyrocketed 5873.08% in 2025.
  • Year by year, Operating Leases stood at $244000.0 in 2023, then plummeted by 78.69% to $52000.0 in 2024, then surged by 5873.08% to $3.1 million in 2025.
  • Business Quant data shows Operating Leases for CGON at $3.1 million in Q4 2025, $3.3 million in Q3 2025, and $706000.0 in Q2 2025.